CN104434930A - 包含24-乙酰泽泻醇A和23-乙酰泽泻醇B的组合物及其在调血脂、制备HMG-CoA抑制剂上的应用 - Google Patents
包含24-乙酰泽泻醇A和23-乙酰泽泻醇B的组合物及其在调血脂、制备HMG-CoA抑制剂上的应用 Download PDFInfo
- Publication number
- CN104434930A CN104434930A CN201410650790.8A CN201410650790A CN104434930A CN 104434930 A CN104434930 A CN 104434930A CN 201410650790 A CN201410650790 A CN 201410650790A CN 104434930 A CN104434930 A CN 104434930A
- Authority
- CN
- China
- Prior art keywords
- alisol
- group
- acetyl
- monoacetate
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 239000008280 blood Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 210000004369 blood Anatomy 0.000 title abstract description 12
- QMCLOHXDDPMAMI-UHFFFAOYSA-N alisol B Natural products CC(C)C(=O)C(O)CC(C)C1=C2CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CC1 QMCLOHXDDPMAMI-UHFFFAOYSA-N 0.000 title abstract 8
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 title description 4
- 239000003112 inhibitor Substances 0.000 title description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 9
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 9
- NLOAQXKIIGTTRE-JSWHPQHOSA-N Alisol b acetate Chemical compound O([C@@H]1[C@@H](OC(C)=O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C NLOAQXKIIGTTRE-JSWHPQHOSA-N 0.000 claims description 59
- NLOAQXKIIGTTRE-UHFFFAOYSA-N Alisol-B-Monoacetat Natural products C=12CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CCC=1C(C)CC(OC(C)=O)C1OC1(C)C NLOAQXKIIGTTRE-UHFFFAOYSA-N 0.000 claims description 59
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 56
- 150000002632 lipids Chemical class 0.000 claims description 20
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 16
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 claims description 12
- 239000000470 constituent Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract description 13
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000037356 lipid metabolism Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000003203 everyday effect Effects 0.000 description 30
- 238000011049 filling Methods 0.000 description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 239000002024 ethyl acetate extract Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- -1 trihydroxy trimethyl glutaryl Chemical group 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000008604 lipoprotein metabolism Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000004279 orbit Anatomy 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 229930188824 alisol Natural products 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 244000233890 Alisma plantago Species 0.000 description 1
- 235000017300 Alisma plantago Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000786103 Steatomys pratensis Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- RNTRDTWDTOZSEV-UHFFFAOYSA-N norphytene Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=C RNTRDTWDTOZSEV-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | 动物数/只 | TC(ng/ml) | TG(ng/ml) | HDL-C(ng/ml) |
空白组 | 11 | 8.94±1.37 | 9.51±1.52 | 68.93±7.91 |
模型组 | 11 | 29.05±1.49▲▲ | 30.59±3.02▲▲ | 17.86±5.59▲▲ |
组别 | HMG-CoA还原酶(U/L) |
空白组 | 113.69±22.34 |
阳性组 | 207.77±30.14** |
模型组 | 487.52±50.17▲▲ |
24A高组 | 287.13±30.15** |
A中组 | 355.54±39.34** |
A低组 | 414.27±51.21** |
23B高组 | 277.03±33.31** |
B中组 | 303.54±31.18** |
B低组 | 405.85±40.23** |
1:10组 | 340.74±75.74** |
1:3组 | 226.64±63.63** |
1:1组 | 380.19±98.87** |
1:20组 | 400.85±40.23** |
1:5组 | 385.11±96.86** |
1:0.5组 | 390.11±83.21** |
1:0.05组 | 398.85±56.67** |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410650790.8A CN104434930B (zh) | 2014-11-14 | 2014-11-14 | 包含24‑乙酰泽泻醇A和23‑乙酰泽泻醇B的组合物及其在调血脂、制备HMG‑CoA抑制剂上的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410650790.8A CN104434930B (zh) | 2014-11-14 | 2014-11-14 | 包含24‑乙酰泽泻醇A和23‑乙酰泽泻醇B的组合物及其在调血脂、制备HMG‑CoA抑制剂上的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104434930A true CN104434930A (zh) | 2015-03-25 |
CN104434930B CN104434930B (zh) | 2017-06-09 |
Family
ID=52882195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410650790.8A Expired - Fee Related CN104434930B (zh) | 2014-11-14 | 2014-11-14 | 包含24‑乙酰泽泻醇A和23‑乙酰泽泻醇B的组合物及其在调血脂、制备HMG‑CoA抑制剂上的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104434930B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108164517A (zh) * | 2018-02-12 | 2018-06-15 | 李化绪 | (2-甲基环己烷-1-基)亚氨基类化合物及其在高脂血症药物中的应用 |
CN108250194A (zh) * | 2018-02-12 | 2018-07-06 | 李化绪 | 一种二氟苯并噻唑类化合物及其在降血脂药物中的应用 |
CN108299405A (zh) * | 2018-02-12 | 2018-07-20 | 李化绪 | 3-对n,n二乙基氨基苯基亚氨基类化合物及其在高脂血症药物中的应用 |
CN108299406A (zh) * | 2018-02-12 | 2018-07-20 | 李化绪 | HMG-CoA还原酶抑制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1247203A (en) * | 1967-09-25 | 1971-09-22 | Takeda Chemical Industries Ltd | Alisol compounds |
CN1872252A (zh) * | 2005-06-03 | 2006-12-06 | 江苏省药物研究所 | 泽泻活性成分组合物及其在医药上应用 |
CN103845340A (zh) * | 2012-12-07 | 2014-06-11 | 上海现代药物制剂工程研究中心有限公司 | 泽泻醇a 24-乙酸酯在制备防治动脉疾病药物中的应用 |
-
2014
- 2014-11-14 CN CN201410650790.8A patent/CN104434930B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1247203A (en) * | 1967-09-25 | 1971-09-22 | Takeda Chemical Industries Ltd | Alisol compounds |
CN1872252A (zh) * | 2005-06-03 | 2006-12-06 | 江苏省药物研究所 | 泽泻活性成分组合物及其在医药上应用 |
CN103845340A (zh) * | 2012-12-07 | 2014-06-11 | 上海现代药物制剂工程研究中心有限公司 | 泽泻醇a 24-乙酸酯在制备防治动脉疾病药物中的应用 |
Non-Patent Citations (4)
Title |
---|
HONG DAN等: "Hypolipidemic effects of Alismatis rhizome on lipid profile in mice fed high-fat diet", 《SAUDI MED J》 * |
么厉等: "《中药材规范化种植(养殖)技术指南》", 31 May 2006, 中国农业出版社 * |
曹晓钢: "山楂及降血脂活性部位的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
辛丹丹等: "国内外降脂药物的研究进展", 《内蒙古中医药》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108164517A (zh) * | 2018-02-12 | 2018-06-15 | 李化绪 | (2-甲基环己烷-1-基)亚氨基类化合物及其在高脂血症药物中的应用 |
CN108250194A (zh) * | 2018-02-12 | 2018-07-06 | 李化绪 | 一种二氟苯并噻唑类化合物及其在降血脂药物中的应用 |
CN108299405A (zh) * | 2018-02-12 | 2018-07-20 | 李化绪 | 3-对n,n二乙基氨基苯基亚氨基类化合物及其在高脂血症药物中的应用 |
CN108299406A (zh) * | 2018-02-12 | 2018-07-20 | 李化绪 | HMG-CoA还原酶抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN104434930B (zh) | 2017-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104434930A (zh) | 包含24-乙酰泽泻醇A和23-乙酰泽泻醇B的组合物及其在调血脂、制备HMG-CoA抑制剂上的应用 | |
CN107365680A (zh) | 一种利用名酒大曲制备的食醋/醋膏及其应用 | |
CN102058631B (zh) | 沙棘叶提取物制剂及其制备方法 | |
CN107753547A (zh) | 改善肠道菌群的皂苷类化合物、制备方法及其应用 | |
CN101836725A (zh) | 红曲渣产品在制备降血脂保健食品方面的应用 | |
CN106727807A (zh) | 一种人参酶解物及其制备工艺和应用 | |
CN101181373B (zh) | 丹皮有效部位药物组合物、其制备方法及应用 | |
CN101119740A (zh) | 中药地榆及其提取物在制备升高红细胞和血红蛋白药物中的应用 | |
CN111973697A (zh) | 中药复方在制备用于防治代谢综合征的药物组合物中的用途 | |
CN106063795B (zh) | 连翘苷、其衍生物、连翘苷与连翘脂素组合物在制备预防或/和治疗高血脂症药物中的应用 | |
CN101057678B (zh) | 一种含有天然植物提取物或单体的组合物 | |
CN102860552A (zh) | 一种荷叶减肥饮料的制备工艺 | |
CN104055947B (zh) | 一种含有葡萄提取物的中药组合物及制备方法 | |
CN101057674B (zh) | 一种用于防治糖尿病的组合物 | |
CN102357110B (zh) | 墨旱莲在制备预防和治疗高脂血症的药物中的用途 | |
CN104739840A (zh) | 积雪草酸制备预防和治疗高血脂症药物及脂肪肝药物的新用途 | |
CN100502867C (zh) | 青藤碱用于抗肿瘤药物的制备 | |
CN101199564B (zh) | 三七花总皂苷在制备治疗高血压病药物中的应用 | |
CN104042684B (zh) | 一种含有绞股蓝提取物的中药组合物及制备方法 | |
CN102091313B (zh) | 紫苏叶与生姜组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
US20120041058A1 (en) | Composition of traditional chinese medicine for reducing blood fat and preparation method thereof | |
CN103505664A (zh) | 一种含有决明子的降血脂组合物及制备方法 | |
CN105456277A (zh) | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 | |
CN102040603B (zh) | 溴化n-邻甲氧羰基苄基四氢小檗碱及其治疗高血脂症的用途 | |
CN107260771A (zh) | 凤尾草总黄酮的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: Building 3, college students science and technology entrepreneurship Park, east side of Yongsheng Road, Dafeng District, Yancheng City, Jiangsu Province 224100 Patentee after: Nanjing University of Chinese Medicine Address before: No. 138 Nanjing City, Jiangsu province 210046 Xianlin Avenue Patentee before: Nanjing University of Chinese Medicine |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 138 Nanjing City, Jiangsu province 210046 Xianlin Avenue Patentee after: Nanjing University of Chinese Medicine Address before: Building 3, college students science and technology entrepreneurship Park, east side of Yongsheng Road, Dafeng District, Yancheng City, Jiangsu Province 224100 Patentee before: Nanjing University of Chinese Medicine |
|
CP02 | Change in the address of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170609 |
|
CF01 | Termination of patent right due to non-payment of annual fee |